Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle

Area of Science:

• Biochemistry
• Pharmacology
• Urology

Background:

• Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are crucial second messengers for smooth muscle relaxation.
• This pathway is vital for cavernous smooth muscle relaxation, essential for erection.

Purpose of the Study:

• To characterize phosphodiesterase (PDE) isoenzymes in human cavernous smooth muscle.
• To evaluate the efficacy of selective PDE inhibitors in inducing smooth muscle relaxation relevant to erectile function.

Main Methods:

• Anion-exchange chromatography (DEAE-Sepharose) for PDE isoenzyme separation.
• Modified PDE assay method (Thompson and Lakey).
• Organ-bath studies to assess the relaxation effects of PDE inhibitors.

Main Results:

• Identified three PDE isoenzymes in human cavernous smooth muscle: PDE III (cGMP-inhibited), PDE IV (cAMP-specific), and PDE V (cGMP-specific).
• All tested PDE inhibitors induced relaxation in isolated human cavernous smooth muscle.
• Quazinone (PDE III inhibitor) showed potency comparable to papaverine (non-selective) and superior to Rolipram (PDE IV) and zaprinast (PDE V).

Conclusions:

• The study elucidates the presence and functional relevance of PDE isoenzymes in human cavernous smooth muscle.
• Selective PDE inhibitors exhibit varying potencies in relaxing cavernous smooth muscle.
• These findings provide a strong rationale for developing selective PDE inhibitors for treating erectile dysfunction.